These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immune checkpoint inhibitors for recurrent endometrial cancer. Mutlu L; Harold J; Tymon-Rosario J; Santin AD Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955 [TBL] [Abstract][Full Text] [Related]
3. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267 [TBL] [Abstract][Full Text] [Related]
4. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Kasherman L; Ahrari S; Lheureux S Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in endometrial cancer. Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; García de Santiago B; Casado Sáenz E Crit Rev Oncol Hematol; 2021 May; 161():103306. PubMed ID: 33839243 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496 [TBL] [Abstract][Full Text] [Related]
7. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574 [TBL] [Abstract][Full Text] [Related]
8. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y; Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813 [TBL] [Abstract][Full Text] [Related]
9. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871 [No Abstract] [Full Text] [Related]
10. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers. Liu YL; Weigelt B Cancer; 2024 May; 130(10):1733-1746. PubMed ID: 38422006 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in the treatment of advanced or recurrent endometrial cancer. Grau-Bejar JF; Farinas-Madrid L; García-Duran C; García-Illescas D; Mazzeo R; Oaknin A Clin Adv Hematol Oncol; 2024 Apr; 22(3):129-139. PubMed ID: 38588272 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer. Oshima K; Yamazaki K Int J Clin Oncol; 2023 Nov; 28(11):1442-1450. PubMed ID: 37668816 [TBL] [Abstract][Full Text] [Related]
13. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer. Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G Front Immunol; 2023; 14():1298524. PubMed ID: 38187388 [TBL] [Abstract][Full Text] [Related]